Tandem Diabetes Care won FDA clearance for a tubeless cartridge and infusion set that convert its existing Mobi pump to on-body wear. The company announced the clearance on November 13. The infusion set is cleared for up to seven days of wear and the cartridge for three days of use. The pump itself stays cleared for both tubed and tubeless infusion.

The system runs Control-IQ+, Tandem's hybrid closed-loop algorithm, which reads interoperable CGM values, predicts glucose 30 minutes out and adjusts delivery. The pump is indicated for ages 2 and up. Control-IQ+ covers type 1 diabetes from age 2 and type 2 diabetes from age 18, and should not be used in patients needing fewer than 5 units of insulin a day or weighing under 20 pounds.

Tandem plans a full US launch in the first half of 2027 and says customers with an in-warranty Mobi will not need a new pump. The sets and cartridges will sell only through pharmacies, and Tandem puts pharmacy coverage for Mobi customers at roughly 50 percent of insured US lives today.

Clearing a wear accessory rather than a new pump is the cheaper route to a new form factor, and it is the kind of predicate strategy worth studying: the algorithm, the pump and the indication all carried over, so the submission turned on the set and cartridge.